Christian Marth, MD, PhD

Articles

Next Steps With Pembrolizumab/Lenvatinib in Endometrial Cancer

April 15th 2024

Christian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm.

Efficacy and Safety Data With Pembrolizumab/Lenvatinib in LEAP-001 of Endometrial Cancer

April 8th 2024

Christian Marth, MD, PhD, discusses efficacy and safety findings from the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer.

Exploring Unmet Needs for the LEAP-001 Trial in Advanced Endometrial Cancer

April 8th 2024

Christian Marth, MD, PhD, discusses the unmet needs that led to the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer and other research efforts of interest.

Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer

April 3rd 2024

Christian Marth, MD, PhD, discusses the differences between mismatch repair–deficient and –proficient subtypes of advanced/recurrent endometrial cancer and other research efforts of interest.

Prognosis and Survival Outcomes for Advanced/Recurrent Endometrial Cancer

April 3rd 2024

Christian Marth, MD, PhD, highlights the prognosis and survival outcomes for patients who are diagnosed with advanced or recurrent endometrial cancer.

Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer

March 19th 2024

Christian Marth, MD, PhD, discusses the LEAP-001 trial of lenvatinib plus pembrolizumab vs chemotherapy in advanced or recurrent endometrial cancer.

Adverse Events Associated With Immunotherapy in the Treatment of Endometrial Cancer

July 4th 2023

Christian Marth, MD, PhD, reviews the adverse effects of pembrolizumab and lenvatinib in the treatment of endometrial cancer, as well as the patient experience with these treatments.

Treatment Strategies in Non-Responders to Chemotherapy

July 4th 2023

Bradley J. Monk, MD, FACS, FACOG, and Christian Marth, MD, PhD, share treatment approaches to patients with endometrial cancer with a low response rate to chemotherapy, highlighting a biomarker-based approach.

Future Outlook for Endometrial Cancer Treatment

June 27th 2023

Experts discuss the possibility to avoid use of chemotherapy by using immunotherapy.

Clinical Trials of Immunotherapies in Endometrial Cancer

June 27th 2023

Christian Marth, MD, PhD, and Bradley J. Monk, MD, FACS, FACOG, discuss data from the NRG GY018 and RUBY trials regarding the use of immunotherapies for the treatment of endometrial cancer.

Chemotherapy Options for Endometrial Cancer

June 20th 2023

Bradley J. Monk, MD, FACS, FACOG, reviews the available chemotherapy options for treating advanced and recurrent endometrial cancer, as well as compares notes with Christian Marth, MD, PhD, on his clinical experience.

An Overview of Endometrial Cancer

June 20th 2023

Christian Marth, MD, PhD, discusses the prevalence of endometrial cancer, as well as the steps that lead to diagnosis.